OH, MY ACHING HEAD! I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE MANAGING HEADACHE IN THE OUTPATIENT SETTING SECONDARY HEADACHES
|
|
- Primrose Hoover
- 6 years ago
- Views:
Transcription
1 1 JUSTIN A. OSSMAN, MD CHATTANOOGA FAMILY MEDICINE UPDATE OH, MY ACHING HEAD! MANAGING HEADACHE IN THE OUTPATIENT SETTING 2 I HAVE NO DISCLOSURES OR CONFLICTS OF INTERESTS TO DECLARE OBJECTIVES International Headache Society (IHS) Classifications Common Headaches Medical and Alternative Therapies Role of Imaging IHS CLASSIFICATIONS PRIMARY HEADACHES Migraine Tension-Type Headache Cluster Headache and other Trigeminal Autonomic Cephalgias Other Primary Headache Disorders 3 4 IHS CLASSIFICATIONS SECONDARY HEADACHES Headache attributed to Trauma Vascular / Non-Vascular Substance or Withdrawal Infection Metabolic Disorder IHS CLASSIFICATIONS TERTIARY HEADACHES Cranial Neuralgias Central and Primary Facial Pain Other Headaches 5 6
2 CHARACTERISTICS Determine if with aura or without aura Lasts 4-72 hours Descriptive terms: Unilateral Pulsating / Throbbing quality Moderate to severe intensity A/w nausea and/or vomiting Photo- / Phonophobia Aggravated with exertional activity Neurovascular headache 5-HT Genetic component Vulnerability > Attack Initiation (Triggers) > Prodrome > with/without Aura > Headache > Resolution > Hangover 7 8 ACUTE Rest Analgesics Antiemetics Triptans Ergotamines Intranasal Lidocaine 4% ACUTE - ANALGESICS OTC Analgesics and NSAIDs NSAID combinations (Anacin, Excedrin) Barbiturate / NSAID combinations (Fioricet) Narcotics Tramadol 9 10 ACUTE - ANTIEMETICS Reglan Promethazine Ondansetron ACUTE - TRIPTANS Almotriptan (Axert): PO Eletriptan (Relpax): PO Frovatriptan (Frova): PO Naratriptan (Amerge): PO Sumatriptan (Imitrex / Treximet / Zecuity): PO, nasal spray, SC, transdermal Rizatriptan (Maxalt): PO, Dissolving wafer Zolmitriptan (Zomig): PO, Dissolving tablet, nasal spray 11 12
3 ACUTE - ERGOT ALKALOIDS Ergotamine (Ergomar): PO Dihydroergotamine (D.H.E. 45 / Migranal): Injectable, intranasal, inhaled (pending FDA approval) PROPHYLAXIS Tricyclic Antidepressants Anti-Epileptics ß-Blockers Ca2+-Channel Blockers NSAIDs Botulinum Toxin A CAM CAM Acupuncture Biofeedback Botox Butterbur Behavioral Tx Feverfew Magnesium CHARACTERISTICS Lasts 30 minutes to 7 days 2 pain characteristics: Pressing or tightening quality Mild to Moderate intensity Bilateral No aggravation w/ routine activity Both: No N/V 1 of Photophobia or Photophobia Physical activity / Yoga Riboflavin (B2) CoQ10 Meditation TENS device TMS Dietary Muscle tension Usually absent any signs of serious underlying condition Trigger control Analgesics +/ Adjuncts Trigger point injections Botulinum toxin A Biofeedback, etc. Physical Therapy Acupuncture 17 18
4 PROPHYLAXIS Amitriptyline Venlafaxine Mirtazapine Trigger Point Injections Behavioral Treatment Acupuncture Physical Tx / OMT TRIGGER POINT INJECTIONS OCCIPITAL NERVE INJECTION Image credits (clockwise from left): burnabyneurology.com, vanderbilthealth.com, intelligentpainsolutions.com CHARACTERISTICS CLUSTER HEADACHE Unilateral in temporal or periorbital area Lasts approx minutes (Untreated) 1 episode QOD to 8 episodes/day Severe pain ( Suicide headache ) Associated Sx: 1 ipsilateral Sx in Eye, Nose, or Face Restlessness or Agitation CLUSTER HEADACHE Vascular dilation Trigeminal nerve stimulation Histamine release Circadian rhythm disturbances Genetics ACUTE CLUSTER HEADACHE Supplemental Oxygen Triptans Intranasal Lidocaine 4% CHRONIC CLUSTER HEADACHE Verapamil Lithium Corticosteroids: PO, Trigger point Deep brain stimulation 23 24
5 PROPHYLAXIS CLUSTER HEADACHE Verapamil Corticosteroids Topiramate Melatonin Gabapentin CHARACTERISTICS MEDICATION OVERUSE HEADACHE (MOH) Nearly daily occurrence Diffuse or dull Usually bilateral Headaches worsen as Tx becomes less effective Typical offenders: OTC / Rx analgesics, Caffeine, Sedatives, Ergotamines MEDICATION OVERUSE HEADACHE Increased excitability of neurons 5-HT mediated MEDICATION OVERUSE HEADACHE Stop offending agent Counsel patient HA may worsen Consider alternative methods of Tx ACR APPROPRIATENESS CRITERIA 29 ROLE OF IMAGING CT brain: Acute Worst headache of my life Post-traumatic MRI brain: New or Chronic w/ or w/o new features and neurologic findings 2/2 sinusitis or mastoiditis Suspected temporal arteritis, meningitis / encephalitis IF ONLY IT WERE THIS SIMPLEÁ 30 NO BRAIN, NO HEADACHE. Anonymous
6 TEXT 31 REFERENCES International Headache Society. "Headache Free". R. Cady, M.D.; K. Farmer, Psy.D AmericanHeadacheSociety.org. Cruse DO, Robert. Acute Treatment of Migraine in Children. UpToDate.com. Blau, J.N. Migraine: theories of pathogenesis. The Lancet. Vol. 339, Issue 8803, Reddy, Doodipala. The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headache. Expert Rev Clin Pharmacy. 2013;6(3): Loder, Elizabeth. Triptan Therapy in Migraine. N Engl J Med. 2010;363: Silberstein, Stephen. Practice Parameter: Evidence-Based Guidelines for Migraine Headache (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55; Maizels, M.; Geiger, AM. Intranasal lidocaine for migraine: A randomized trial and open-label follow-up. Headache Sep;39(8): TEXT 32 REFERENCES Armstrong, Laura; Gossard, Geraldine. Taking an integrative approach to migraine headaches. The Journal of Family Practice. 2016;65(3): Jackson, JL, et al. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a metaanalysis. JAMA Apr 25;307(16): Paul Millea and Jonathan Brodie. Tension-Type Headache. Am Fam Physician. 2002;66: ,805. Frederick Taylor. Tension-Type Headache In Adults: Acute Treatment. UpToDate.com. Accessed Dec Frederick Taylor. Tension-Type Headache In Adults: Preventive Treatment. UpToDate.com. Accessed Dec Karadas et al. Lidocaine injection of pericardial myofascial trigger points in the treatment of frequent episodic tension-type headache. The Journal of Headache and Pain. 2013;14:44. Jacqueline Weaver-Agostoni. Cluster Headache. Am Fam Physician. 2013;88(2): Gadsby, Peter. Treatment of Cluster Headache. Information for Health Care Professionals. American Headache Society. Robbins, L. Intranasal Lidocaine for Cluster Headache. Headache: the Journal of Headache and Face Pain. 1995;35(2): Srikiatkhachorn, A, et al. Pathophysiology of Medication Overuse Headache: An Update. Headache. 2014;541: American College of Radiology ACR Appropriateness Criteria.
MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationFaculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.
Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu
More informationCase Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches
Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily
More informationHeadache. Section 1. Migraine headache. Clinical presentation
Section 1 Headache Migraine headache 1 Clinical presentation It is important to recognize just how significant a problem migraine headache is. It has been estimated that migraine affects 11% of the United
More informationA case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:
Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationPage: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)
Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationHeadache A Practical Approach
Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:
More informationGoals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders
Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine
More informationTreatment of Primary Headache Syndromes
Presenter Disclosure Information 2:45 3:45pm Treatment of Primary Headache Syndromes SPEAKER Gerald W. Smetana, MD The following relationships exist related to this presentation: Gerald W.Smetana, MD,
More informationIndex. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.
Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369
More informationChronic Daily Headaches
Chronic Daily Headaches ANWARUL HAQ, MD, MRCP(UK), FAHS DIRECTOR BAYLOR HEADACHE CENTER, DALLAS, TEXAS DISCLOSURES: None OBJECTIVES AT THE CONCLUSION OF THIS ACTIVITY, PARTICIPANTS WILL BE ABLE TO: define
More informationปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา
ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา 1 CONTENT 1 2 3 Chronic Daily Headache Medical Overused Headache Management Headaches are one of the most common symptoms List
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationStrategies in Migraine Care
Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives
More informationHeadache Questionnaire
Date: All Headache Patients We would appreciate your cooperation in filling out this form. In our evaluation of headache, your history is typically our most valuable tool for diagnosis and subsequent treatment.
More informationClinical Learning Days November 10, 2017
Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion
More informationCOLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE
COLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE HEADACHE CHARACTERISTICS Frequency and Severity 1. At what AGE did you get your first headache, of ANY kind? 2. At what AGE did your headaches
More informationMigranal Nasal Spray. Migranal Nasal Spray (dihydroergotamine) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: June 22, 2017 Migranal Nasal Spray
More informationRegulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationHeadache and Facial Pain. Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology
Headache and Facial Pain Mohammed ALEssa MBBS, FRCSC Assistant Professor Consultant Otolaryngology,Head & Neck Surgical Oncology Introduction It is the most common neurologic complain The diagnosis usually
More informationHeadaches in the Pediatric Emergency Dept
Headaches in Children February 23, 2011 Jinny Tavee, MD Associate Professor Neuromuscular Center Cleveland Clinic Foundation Cleveland, OH 1 Headaches in the Pediatric Emergency Dept Burton Gutierrez Kan
More informationABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 12/11/2018 CLASS: Neurological Disorders REVIEW HISTORY 9/17, 12/16, 9/15, 2/15, 2/10, LOB: MCL
More information6/4/2018. Headache. Headaches. Headache. Migraine Headaches. Headache. Red Flag signs and symptoms. Imaging CT without contrast.
Presented by M.D. Shepherd, M.D. OH MY ACHING HEAD! Estimated that one half of the adult population is affected by a headache disorder International Society Classification Primary : Tension s 40% of the
More informationTears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE
Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE IHS Classification 1989 (updated 2004) Primary Headaches 4 categories Migraine Tension-type Cluster and other trigeminal
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationTriptan Quantity Limit
*- Florida Healthy Kids Triptan Quantity Limit Override(s) Quantity Limit Approval Duration 1 year Oral Tablets Axert (almotriptan) tablets Relpax (eletriptan) tablets 6 tablets (6.25 mg) 12 tablets (12.5
More informationHeadache. Headache Case. Migraine Headache. Eric Kraus, MD. Types» Without aura (common)» With aura (classic)
Headache Eric Kraus, MD Headache Case This 23 year-old female has headaches behind the right eye that cause her to lay down in a quiet room. They have a throbbing quality and she may vomit. Migraine Headache
More informationPrevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.
Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationI have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.
I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationAbortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
More informationTriptans Quantity Limit Program Summary
Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without
More informationPharmacy Medical Necessity Guidelines: Migraine Medications
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationUTILIZATION MANAGEMENT CRITERIA
SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),
More informationUnderstanding Migraines and Treatment Options. Simplified Diagnosis of Migraine. Migraine Prevalence American Migraine Study II
Understanding Migraines and Treatment Options Deborah C. Zajac, RN-BC Center for Headache and Pain Neurological Institute Cleveland Clinic Simplified Diagnosis of Migraine Any person with a stable pattern
More informationManagement of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More informationAnti-Migraine Agents
DRUG POLICY BENEFIT APPLICATION Anti-Migraine Agents Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationHeadache. Susan Hickenbottom MD, MS February 24, 2015
Headache Susan Hickenbottom MD, MS February 24, 2015 Epidemiology One of most common complaints in primary care 90% of US population 50% at least one severe 25% recurrent disabling attacks 5% chronic daily
More informationA synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline. Scottish intercollegiate Guidelines Network SIGN
A synopsis of: Diagnosis and Management of Headaches in Adults: A national clinical guideline Scottish intercollegiate Guidelines Network SIGN November 2008. PETER FRAMPTON MSc MCOptom BAppSc (Optom)(AUS)
More informationHEADACHE: Benign or Severe Dr Gobinda Chandra Roy
HEADACHE: Benign or Severe Dr Gobinda Chandra Roy Associate Professor, Department of Medicine, Shaheed Suhrawardy Medical College and Hospital Outlines 1. Introduction 2. Classification of headache 3.
More informationZomig. Zomig / Zomig-ZMT (zolmitriptan) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: March 16, 2018 Zomig Description Zomig / Zomig-ZMT
More informationMigraine, Tension, and Cluster Headache: Primary Care for Primary Headaches. Jonathon M. Firnhaber, MD, FAAFP
Migraine, Tension, and Cluster Headache: Primary Care for Primary Headaches Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Utilize evidence-based strategies to diagnose patients presenting with
More informationÇiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE
Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact
More informationHeadache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, II. Management of Refractory Headaches
Headache Master School Japan-Osaka 2016 (HMSJ-Osaka2016) October 23, 2016 II. Management of Refractory Headaches Case presentation 1: A case of intractable daily-persistent headache Keio University School
More informationPage: 1 of 5. Sumatriptan Tablets and Nasal Spray (Imitrex) / sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan (Imitrex / Treximet) Page: 1 of 5 Last Review Date: September 12, 2014 Sumatriptan
More informationClinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationZomig. Zomig / Zomig-ZMT (zolmitriptan) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: November 30, 2018 Zomig Description Zomig / Zomig-ZMT
More information2008 Migraine Update Migraine Update Migraine Update. Epidemiology. Yousef Mohammad MD., MSc. Epidemiology
2008 Migraine Update Yousef Mohammad MD., MSc Assistant Professor of Neurology Ohio State University Medical Center 2008 Migraine Update Epidemiology 2008 Migraine Update Epidemiology Abortive Treatment
More informationClinical Policy: Triptans Reference Number: CP.HNMC.217 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.HNMC.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationDisclosures. Objectives 6/2/2017
Classification: Migraine and Trigeminal Autonomic Cephalalgias Lauren Doyle Strauss, DO, FAHS Assistant Professor, Child Neurology Assistant Director, Child Neurology Residency @StraussHeadache No disclosures
More informationClinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More information~ ColumbiaDoctors Adult New Patient Intake Form Patient Information
~ ColumbiaDoctors Adult New Patient Intake Form Patient Information Last Name: First Name: DOB: Gender: Home Phone: Mobile Phone: ---------- Preferred Phone: Home or Mobile (circle one) Email: -----------
More informationHeadache evaluation and management after concussion. Assistant Professor
Headache evaluation and management after concussion Juliette Preston, M.D. Assistant Professor OHSU Headache Center OVERVIEW Introduction Definition Acute post-traumatic headache Red flags Persistent post-traumatic
More informationFINANCIAL DISCLOSURE. No relevant financial relationships
Sleep and Headache Paul Mathew, MD, FAHS Director of Continuing Medical Education John R. Graham Headache Center Brigham & Women s Hospital Director of Headache Medicine Cambridge Health Alliance Harvard
More information1. On how many days in the last 3 months did you miss work or school because of your headaches?
The Migraine Disability Assessment Test The MIDAS (Migraine Disability Assessment) questionnaire was put together to help you measure the impact your headaches have on your life. The information on this
More informationMigraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital
Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet
More informationMaxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Maxalt Page: 1 of 5 Last Review Date: March 18, 2016 Maxalt Description Maxalt / Maxalt-MLT (rizatriptan)
More informationOutpatient Headache Care Guideline
1 Outpatient Care Guideline Inclusion criteria: children > 3 yrs with headaches Is urgent emergency department, neuroimaging, or Neurology consultation indicated? Referral to ED if: New severe headache
More informationReviews/Evaluations. Medication-Overuse Headache
Reviews/Evaluations Medication-Overuse Headache Population-based studies suggest that the prevalence of chronic daily headache is 3-5%(1,2). Drug-induced headaches are the most common cause of chronic
More informationTREXIMET UTILIZATION MANAGEMENT CRITERIA
TREXIMET UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: 5HT1 agonists Treximet (sumatriptan/naproxen sodium) 85 mg / 500 mg tablet FDA INDICATIONS: Sumatriptan/naproxen is indicated
More information10/31/2017 PRIMARY CARE AND HEADACHE DISCLOSURES WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Primary Care 67%
PRIMARY CARE AND HEADACHE Sonja Potrebic MD PhD Regional Headache Specialist Kaiser LAMC 1 WHERE DO THOSE WITH HEADACHE SEEK MEDICAL CARE? Column1 Primary Care 67% Primary Care Headache Specialty Other
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Triptans: almotriptan, Amerge, Axert, Frova,
More informationCurrent Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN
Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality
More informationMEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache
MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine
More informationApproach to a Patient with Headache
Approach to a Patient with Headache J.D. Bartleson, MD Professor of Neurology Mayo Clinic College of Medicine 15 th Annual Internal Medicine Conference March 25, 2018 Boca Raton, FL 2014 MFMER slide-1
More informationClinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.
OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory
More informationMedication For Migraine Chart: Table 1: Acute Treatment when the attack begins
Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation
More informationEmerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management
Emerging Challenges in Primary Care: 2017 Brainstorm: A Symposium on Migraine Treatment and Management 1 Faculty Jeff Unger, MD, ABFM, FACE Director, Unger Primary Care Medical Group Rancho Cucamonga,
More informationMEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache
MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended
More informationShort Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment
Clinical Highlights 1. Headache is diagnosed by history and physical examination with limited need for imaging or laboratory tests. 2. Warning signs of possible disorder other than primary headache are:
More informationIshaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert
Ishaq Abu Arafeh Consultant Paediatrician Royal Hospital for Children, Glasgow Forth Valley Royal Hospital, Larbert Childhood headache: Is it really difficult to manage? It shouldn t be... But it can be...
More informationBy Nathan Hall Associate Editor
By Nathan Hall Associate Editor 34 Practical Neurology March 2005 These new rules may change the definition of head pain, but some practitioners may find the new guidelines themselves to be a source of
More informationTrigeminal Autonomic Cephalalgias. Disclosures. Objectives 6/20/2018. Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018
Trigeminal Autonomic Cephalalgias Rashmi Halker Singh, MD FAHS UCNS Review Course June 2018 Disclosures Honoraria from Allergan and Amgen for advisory board, Current Neurology and Neuroscience Reports
More informationAdult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention
Adult with headache Problem-specific video guides to diagnosing patients and helping them with management and prevention London Strategic Clinical Networks London Neuroscience Strategic Clinical Network
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Description Sumatriptan
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationIMITREX UTILIZATION MANAGEMENT CRITERIA
IMITREX UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: 5HT1 agonists BRAND NAME: Imitrex 4 mg injection kit or refill (Generic) (sumatriptan) 6 mg injection kit or refill Injection vial (1 dose) 5 mg nasal
More informationControlling Migraine Pain
Migraine Stats Controlling Migraine Pain Alan Zacharias, M.D. Associated Neurologists, Boulder Community Health 303-622-3365 Women 15% Men 5% Usually starts in 2 nd and 3 rd Decade Major Impact on days
More information10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD
Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen
More informationGeneral Patient Information Dr. David A. Branch, M.D.
General Patient Information Dr. David A. Branch, M.D. **Please Print** Patient Name: Date of Birth: Social Security # Email Address: Patient Address: _ City: State: Zip Code: Phone : Marital Status: S
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan
More informationMEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache
MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache Measure Description Percentage of patients age 18 years old and older with a diagnosis of primary headache
More informationOveruse of barbiturate and opioid containing medications for primary headache disorders Description
Measure Title Overuse of barbiturate and opioid containing medications for primary headache disorders Description Percentage of s age 12 years and older with a diagnosis of primary headache who were prescribed
More informationUnderstanding Migraines
Understanding Migraines Migraine is a severe headache syndrome that recurs. Migraine headaches are usually throbbing, but may also be described as exploding, shooting, or squeezing. Migraine headaches
More informationDifferential Diagnosis of Headaches
Angela Nelson, MSN, RN, CCRN, ACNP-BC, FCCM, FAANP Acute Care Nurse Practitioner Department of Neurosurgery AANP 2016 National Conference San Antonio, Texas June 21-26 Differential Diagnosis of Headaches
More informationFarjam Farzam, M.D. Pediatric Neurology
Headaches in Children Farjam Farzam, M.D. Pediatric Neurology University of Kentucky Headaches in Children Common complaint in pediatric population. All age groups. 2-3 years old. Teenagers/Adolescents.
More informationCan I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017
Can I send this headache patient home? Dr Nicola Giffin Consultant Neurologist Bath, Nov 2017 SAH v benign thunderclap headaches Other pathologies not apparent on CT Severe primary headaches: management
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 5 Last Review Date: December 2, 2016 Sumatriptan Description Sumatriptan
More informationOutline. Etiology. General information. Definition 4/13/2012
Outline Dr. Susan Fralick-Ball, PsyD, MSN, RN, CH, CLNC PsychMedEd for Advance 2012 Etiology, Stages & Classifications of Migraines Differential Pathophysiology from other Headaches Current Treatment Therapies
More information11. HEADACHE 1. Pablo Lapuerta, MD, Steven Asch, MD, MPH, and Kenneth Clark, MD, MPH
11. HEADACHE 1 Pablo Lapuerta, MD, Steven Asch, MD, MPH, and Kenneth Clark, MD, MPH We identified articles on the evaluation and management of headache by conducting a MEDLINE search of English language
More informationMigraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification
28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification
More informationMIGRAINE A MYSTERY HEADACHE
MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)
More informationHeadache Pain Generators
Objectives 1. Define the major categories of headache. 2. Take a history directed at characterizing a headache pattern in an individual patient and identify the cause or triggers of the headache. 3. Understand
More informationAn Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California
An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect
More information